Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report.
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ adverse effects
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Lichenoid Eruptions
/ chemically induced
Male
Melanoma
/ drug therapy
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Skin Neoplasms
/ drug therapy
Treatment Outcome
Ultraviolet Therapy
autoimmunity
case reports
immunotherapy
inflammation
melanoma
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
accepted:
10
02
2021
entrez:
27
3
2021
pubmed:
28
3
2021
medline:
18
12
2021
Statut:
ppublish
Résumé
Treatment with programmed cell death 1 inhibitors is associated with a wide range of cutaneous immune-related adverse events, with lichenoid eruptions representing one of the major cutaneous toxicities. We describe the case of an 81-year-old man with metastatic melanoma treated with pembrolizumab who subsequently developed a delayed-onset generalized lichenoid dermatitis. After failing multiple lines of systemic immunosuppression, narrowband ultraviolet B (NBUVB) phototherapy three times per week for 17 sessions resulted in a significant clinical response in his cutaneous eruption and was well tolerated. NBUVB is a safe, lower-cost modality that induces local, skin-specific immunosuppression without the toxicities of traditional systemic immunosuppressive agents. To date, this is the first report of use of NBUVB in immune-related lichenoid dermatitis resistant to multiple standard therapies.
Identifiants
pubmed: 33771890
pii: jitc-2020-001831
doi: 10.1136/jitc-2020-001831
pmc: PMC7996651
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Immune Checkpoint Inhibitors
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
pembrolizumab
DPT0O3T46P
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Front Oncol. 2018 Sep 25;8:405
pubmed: 30319970
JAMA Dermatol. 2016 Oct 1;152(10):1128-1136
pubmed: 27411054
J Am Acad Dermatol. 2019 Apr;80(4):990-997
pubmed: 30399387
Front Immunol. 2019 Jul 31;10:1808
pubmed: 31417572
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
J Am Acad Dermatol. 2016 Mar;74(3):455-61.e1
pubmed: 26793994
Photodermatol Photoimmunol Photomed. 2005 Oct;21(5):260-6
pubmed: 16149939
Arch Dermatol Res. 2005 Jul;297(1):39-42
pubmed: 15889264
J Dermatol Sci. 2009 May;54(2):76-87
pubmed: 19303745
Nat Rev Clin Oncol. 2020 Aug;17(8):504-515
pubmed: 32246128